Physician profile
Deisy Guzman
NPI 1518639376
$2,873.18
in general payments reported to CMS, 2019-2025
21 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,242 · 2024: $1,011 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $654.22 | 2023-2025 | Airsupra, Farxiga, Andexxa |
| Novo Nordisk INC | $337.80 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $337.09 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $307.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $208.27 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $179.88 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $164.16 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $159.83 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.27 | 2023-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $72.51 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $64.75 | 2023-2025 | Freestyle Libre |
| Idorsia Pharmaceuticals US INC | $60.96 | 2023 | Quviviq |
| Pfizer INC. | $55.35 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $40.56 | 2023-2025 | Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $38.36 | 2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $21.20 | 2024 | Immunocap |
| Insightec,INC | $19.31 | 2025 | Exablate |
| Amarin Pharma, INC. | $18.77 | 2023 | |
| Ibsa Pharma INC. | $18.63 | 2024 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $16.33 | 2023 | |
| Merck Sharp & Dohme LLC | $15.38 | 2023 | Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deisy Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.